Drugs in Dev.
Dermatology
Phase I/ Phase II
Israel 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BX005
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Maruho
Deal Size : Inapplicable
Deal Type : Inapplicable
IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis
Details : BX005 is currently in the final stages of GMP production. The Company continues to expect the first data readout from its Phase 1/2 proof-of-concept trial evaluating the safety and efficacy.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : BX005
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Maruho
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BX005-A
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Maruho
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
Details : BX005-A is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : BX005-A
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Maruho
Deal Size : Inapplicable
Deal Type : Inapplicable
